Sunday, January 29, 2023
Homehealth and sciencePharma stock investors brace for billions in heartburn drug litigation charges

Pharma stock investors brace for billions in heartburn drug litigation charges

  • Shares of GSK, Sanofi and Haleon all sold off sharply this week amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac.
  • This has been a known issue bumbling in the background for years but investor concern exploded this week in the lead-up to the first scheduled legal proceeding.
  • For many investors and analysts, this ordeal brings back memories of the Bayer Roundup saga.

In this article

RELATED ARTICLES

Most Popular